Treace Medical Concepts (NASDAQ:TMCI) Releases Earnings Results, Beats Estimates By $0.03 EPS

Treace Medical Concepts (NASDAQ:TMCI) announced its earnings results on Friday. The company reported ($0.28) EPS for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.03, FiscalAI reports. The business had revenue of $47.20 million during the quarter, compared to analysts’ expectations of $45.96 million. Treace Medical Concepts had a negative net margin of 27.74% and a negative return on equity of 59.91%.

Here are the key takeaways from Treace Medical Concepts’ conference call:

• Q1 revenue was $47.2 million, down ~10% year‑over‑year, with a net loss of $18.0 million and an adjusted EBITDA loss of $5.5 million, driven by lower bunion kit volumes and a shift toward lower‑priced products.
• Management reaffirmed full‑year 2026 guidance of $202–$212M in revenue (‑5% to 0% vs. 2025) and expects adjusted EBITDA loss of $4–$6M, while targeting a roughly 50% reduction in cash usage versus 2025.
• Commercial traction is building for the 2025 product launches — about 35% of Lapiplasty surgeons have adopted at least one of the three new bunion systems (up from 25% in Q4), and ~30% of new surgeons who started with those systems have also used Lapiplasty, indicating early pull‑through.
• The product roadmap is expanding — full commercialization of SuperBite and SpeedXM is expected in Q3 and Lapiplasty Lightning later this year, collectively increasing the addressable market by roughly $300M and opening access to higher‑ASP midfoot and hindfoot procedures.
• Management noted persistent macro pressure on elective procedures and an ASP/mix headwind from rapid adoption of lower‑priced MIS products that pressured top‑line results, though they expect these dynamics to abate in the back half and for growth to return in Q4.

Treace Medical Concepts Trading Up 4.7%

NASDAQ:TMCI traded up $0.09 during mid-day trading on Friday, reaching $2.01. The company’s stock had a trading volume of 763,851 shares, compared to its average volume of 780,081. The company’s fifty day simple moving average is $1.62 and its two-hundred day simple moving average is $2.65. The company has a debt-to-equity ratio of 0.64, a current ratio of 4.31 and a quick ratio of 3.13. Treace Medical Concepts has a twelve month low of $1.17 and a twelve month high of $7.78. The stock has a market cap of $130.21 million, a P/E ratio of -2.14 and a beta of 1.10.

Analysts Set New Price Targets

TMCI has been the subject of several analyst reports. Wall Street Zen upgraded Treace Medical Concepts from a “strong sell” rating to a “sell” rating in a research note on Monday, April 27th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Treace Medical Concepts in a research report on Monday, April 20th. Finally, Lake Street Capital decreased their price objective on shares of Treace Medical Concepts from $7.50 to $7.00 and set a “buy” rating on the stock in a research report on Monday, March 2nd. One investment analyst has rated the stock with a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, Treace Medical Concepts has a consensus rating of “Reduce” and a consensus price target of $4.77.

Institutional Investors Weigh In On Treace Medical Concepts

A number of institutional investors have recently added to or reduced their stakes in TMCI. AQR Capital Management LLC purchased a new stake in shares of Treace Medical Concepts during the 1st quarter worth about $491,000. Millennium Management LLC grew its holdings in Treace Medical Concepts by 35.3% during the 1st quarter. Millennium Management LLC now owns 444,887 shares of the company’s stock valued at $3,733,000 after purchasing an additional 116,114 shares in the last quarter. Russell Investments Group Ltd. grew its stake in shares of Treace Medical Concepts by 133,241.9% during the second quarter. Russell Investments Group Ltd. now owns 41,336 shares of the company’s stock valued at $243,000 after acquiring an additional 41,305 shares in the last quarter. Invesco Ltd. increased its holdings in Treace Medical Concepts by 18.6% during the 2nd quarter. Invesco Ltd. now owns 15,051 shares of the company’s stock worth $88,000 after purchasing an additional 2,362 shares during the last quarter. Finally, Marshall Wace LLP increased its stake in shares of Treace Medical Concepts by 256.2% in the second quarter. Marshall Wace LLP now owns 135,877 shares of the company’s stock worth $799,000 after buying an additional 97,729 shares during the last quarter. Hedge funds and other institutional investors own 84.08% of the company’s stock.

Treace Medical Concepts Company Profile

Treace Medical Concepts, Inc is a medical technology company specializing in the development and commercialization of innovative surgical solutions for foot and ankle conditions. The company’s flagship product, the Lapiplasty 3D Bunion Correction System, addresses the underlying joint instability that causes bunion deformity through a patented, multi-plane correction approach. The system combines proprietary instrumentation, fixation plates, and a comprehensive surgical protocol designed to improve patient outcomes and reduce recurrence rates.

The Lapiplasty System has received clearance from the U.S.